MPT Funding Opportunities

We continue to identify and share funding opportunities as they arise to help advance the MPT field. The items below are listed from the earliest to latest release dates, then earliest to latest application due dates. We encourage you to browse the below and welcome you to This email address is being protected from spambots. You need JavaScript enabled to view it. if you hear of any new opportunities.


Microbicide R&D

The Office of HIV/AIDS (GH/OHA) is bringing together a collaboration of partners that will accelerate the research and development (R&D) of new HIV prevention products, like anti-infective MPTs, that women can choose to protect themselves, and address the continuing and disproportionately high rates of HIV incidence in women, especially adolescent girls and young women in sub-Saharan Africa. Learn more!

  • A&A Plan ID#: AA-311278
  • Release Date: 1 February 2021
  • Letters of Intent Due: TBA
  • Application Due: TBA

Introduction to Access

The Office of HIV/AIDS (GH/OHA) will be supporting a consortium of diverse organizations and stakeholders to synergistically advance the introduction of new and existing biomedical prevention products, like anti-infective MPTs, and approaches while proactively addressing challenges and gaps that delay or prevent introduction of and access to these HIV prevention products. Learn more!

  • A&A Plan ID#: AA-313911
  • Release Date: 19 February 2021
  • Letters of Intent Due: TBA
  • Application Due: TBA

NIH HIV Prevention Trials Network

The HPTN is calling for new research concepts from HPTN and non-HPTN affiliated investigators. Submissions that fit HPTN’s mission, objectives, and scientific priorities as well as address any of the research pillars below will be considered. Learn more!

  • Identifying novel antiretroviral (ARV)-based methods and delivery systems for HIV prevention
  • Developing multipurpose prevention technologies for HIV prevention as well as for contraception, prevention of other sexually transmitted infections or opioid dependence
  • Evaluating broadly neutralizing antibodies alone or in a combination that prevent HIV acquisition, in collaboration with the HIV Vaccine Trials Network
  • Designing and conducting population-specific integrated strategy studies that combine biomedical, socio-behavioral, and structural interventions for HIV prevention to maximize their effectiveness
  • Funding Opportunity #: NA
  • Open Date: 11 January 2021
  • Letters of Intent Due: 1 March 2021
  • Application Due: 5 April 2021

Biological Testing Facility (X01 Clinical Trial Not Allowed)

The Eunice Kennedy Shriver National Institute of Child Health and Human Development’s (NICHD) state-of-the art Biological Testing Facility supports female and/or male non-hormonal contraception development, including MPTs. This opportunity is to support the enablement of an IND/IDE study of a pre-clinical candidate that offers a safe, non-hormonal based therapy for female and/or male contraception that acts prior to fertilization and does not act via the hypothalamic-pituitary-gonadal axis. Additional details can be found at www.GRANTS.gov by searching within “Search Grants” for Funding Opportunity Number: PAR-21-078, then clicking on the opportunity number.

  • Funding Opportunity #: PAR-21-078
  • Open Date: 15 December 2020
  • Letters of Intent Due: Not Applicable
  • Application Due: 15 July 2021, 14 January 2022, 15 July 2022

Contraception Development Research Center Program (P50 Clinical Trial Optional)

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is seeking to support and facilitate multidisciplinary approaches towards the development of new and/or improved contraceptive methods for women and men through the formation of a Contraceptive Research Development Center. The NICHD is accepting applications including translational studies to facilitate the pre-clinical to clinical transition and increase the likelihood of clinical success and sociobehavioral and market research to test user acceptability for contraceptive products being developed. The Center will also serve as a national resource for development of early-stage investigators electing to pursue careers in contraceptive research. Applications focused on the late-stage pre-clinical development or clinical development of a single non-hormonal MPT with both contraceptive and anti-infective properties are of high priority. Additional details can be found at www.GRANTS.gov by searching within “Search Grants” for Funding Opportunity Number: RFA-HD-22-003, then clicking on the opportunity number.

  • Funding Opportunity #: RFA-HD-22-003
  • Open Date: 28 February 2021
  • Letters of Intent Due: 29 October 2021
  • Application Due: 29 November 2021

Family Planning and Reproductive Health Methods APS

The United States Agency for International Development (USAID) is seeking to support the research, development, and introduction of technologies and approaches that better meet the needs of women as their sexual and reproductive health concerns change over time. This includes the development of multipurpose prevention technologies (MPTs) that address the simultaneous risks of unintended pregnancy, HIV, and other sexually transmitted infections (STIs)—particularly Herpes Simplex Virus (HSV) and Human Papillomavirus (HPV). Additional details can be found on the Round 4 call for concept papers at www.GRANTS.gov by searching within “Search Grants” for Funding Opportunity Number: SOL-OAA-13-000024, then clicking on the opportunity number.

  • Funding Opportunity #: SOL-OAA-13-000024
  • Open Date: 15 January 2013
  • Concept Papers Due: 14 February 2020
  • Application Due: 14 January 2023

Resource Search

 
 
Keyword Search
 

655 resource(s) found

The IMPT is the first & only initiative dedicated to advancing the field of multipurpose prevention technologies (MPTs), products that combine HIV prevention, other STI prevention, and contraception.

IMPT Secretariat
1750 Howe Avenue, Suite 550
Sacramento, CA 95825
IMPT@cami-health.org

The Initiative for Multipurpose Prevention Technologies (IMPT) is a project of CAMI Health, a social impact organization dedicated to improving the health of women and their families worldwide. CAMI Health is housed at the Public Health Institute (PHI).

This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government.
© Copyright 2020, Public Health Institute / CAMI Health / IMPT Secretariat. All rights reserved.